$154 Million is the total value of Tamarack Advisers, LP's 21 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 73.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | SPY Nov3 400.0 Pput | $64,122,000 | – | 150,000 | +100.0% | 41.52% | – | |
| New | BDX Oct3 275.0 Ccall | $16,804,450 | – | 65,000 | +100.0% | 10.88% | – | |
| New | DXCM Oct3 110.0Ccall | $9,330,000 | – | 100,000 | +100.0% | 6.04% | – | |
| VTRS | Sell | VIATRIS ORDequity | $6,655,500 | -46.6% | 675,000 | -46.0% | 4.31% | +11.8% |
| BDX | Buy | BECTON DICKINSON ORDequity | $6,463,250 | +63.2% | 25,000 | +66.7% | 4.18% | +241.9% |
| New | VTRS Oct3 11.0 Ccall | $5,916,000 | – | 600,000 | +100.0% | 3.83% | – | |
| MDRX | Sell | VERADIGM ORDequity | $5,715,900 | -51.2% | 435,000 | -53.2% | 3.70% | +2.2% |
| MCK | Sell | MCKESSON ORDequity | $4,783,350 | -20.0% | 11,000 | -21.4% | 3.10% | +67.6% |
| STRM | STREAMLINE HEALTH SOLUTIONS ORDequity | $4,770,628 | -23.8% | 4,930,882 | 0.0% | 3.09% | +59.6% | |
| New | TLT Oct3 100.0 Ccall | $4,434,500 | – | 50,000 | +100.0% | 2.87% | – | |
| COLL | Sell | COLLEGIUM PHARMACEUTICAL ORDequity | $4,134,750 | -48.7% | 185,000 | -50.7% | 2.68% | +7.5% |
| PHR | Sell | PHREESIA ORDequity | $4,016,200 | -55.3% | 215,000 | -25.9% | 2.60% | -6.4% |
| ANGO | Buy | ANGIODYNAMICS ORDequity | $3,472,250 | -28.4% | 475,000 | +2.2% | 2.25% | +50.0% |
| TCMD | Sell | TACTILE SYSTEMS TECHNOLOGY ORDequity | $3,361,069 | -55.1% | 239,222 | -20.3% | 2.18% | -5.8% |
| MDRX | Buy | MDRX Oct3 15.0 Ccall | $2,628,000 | +108.6% | 200,000 | +100.0% | 1.70% | +337.5% |
| ATRC | Sell | ATRICURE ORDequity | $1,752,000 | -58.2% | 40,000 | -52.9% | 1.14% | -12.5% |
| SNY | Sell | SANOFI ADR REP 1 1/2 ORDequity | $1,609,200 | -68.6% | 30,000 | -68.4% | 1.04% | -34.2% |
| THC | Sell | TENET HEALTHCARE ORDequity | $1,317,800 | -83.0% | 20,000 | -78.9% | 0.85% | -64.3% |
| SIBN | Sell | SI BONE ORDequity | $1,062,000 | -80.3% | 50,000 | -75.0% | 0.69% | -58.8% |
| CERS | Sell | CERUS ORDequity | $1,053,000 | -75.5% | 650,000 | -62.9% | 0.68% | -48.7% |
| New | TEVA Oct3 10.0 Ccall | $1,020,000 | – | 100,000 | +100.0% | 0.66% | – | |
| Exit | KENVUE ORDequity | $0 | – | -1,000 | -100.0% | -0.01% | – | |
| Exit | SOMALOGIC EQY WARRANTcall | $0 | – | -20,000 | -100.0% | -0.01% | – | |
| Exit | SOMALOGIC CL A ORDequity | $0 | – | -110,000 | -100.0% | -0.08% | – | |
| OLK | Exit | OLINK HOLDING AB PUBL ADRequity | $0 | – | -15,000 | -100.0% | -0.09% | – |
| TECH | Exit | BIO TECHNE ORDequity | $0 | – | -4,000 | -100.0% | -0.10% | – |
| BIO | Exit | BIO RAD LABORATORIES CL A ORDequity | $0 | – | -2,000 | -100.0% | -0.23% | – |
| SPB | Exit | SPECTRUM BRANDS HOLDINGS ORDequity | $0 | – | -10,000 | -100.0% | -0.24% | – |
| Exit | DOCGO ORDequity | $0 | – | -135,000 | -100.0% | -0.39% | – | |
| RIGL | Exit | RIGEL PHARMACEUTICALS ORDequity | $0 | – | -1,250,000 | -100.0% | -0.50% | – |
| DXCM | Exit | DEXCOM ORDequity | $0 | – | -16,000 | -100.0% | -0.64% | – |
| IRWD | Exit | IRONWOOD PHARMA CL A ORDequity | $0 | – | -225,000 | -100.0% | -0.74% | – |
| INMD | Exit | INMODE ORDequity | $0 | – | -75,000 | -100.0% | -0.87% | – |
| ALKS | Exit | ALKERMES ORDequity | $0 | – | -100,000 | -100.0% | -0.97% | – |
| TEVA | Exit | TEVA PHARMA IND ADR REP 1 ORDequity | $0 | – | -450,000 | -100.0% | -1.05% | – |
| RDNT | Exit | RADNET ORDequity | $0 | – | -140,000 | -100.0% | -1.41% | – |
| ABT | Exit | ABBOTT LABORATORIES ORDequity | $0 | – | -45,000 | -100.0% | -1.52% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL ORDequity | $0 | – | -75,000 | -100.0% | -2.01% | – |
| TLT | Exit | iShares 20 Plus Year Treasury Bond ETF Sep3 110.0 Ccall | $0 | – | -150,000 | -100.0% | -4.77% | – |
| SPY | Exit | SPDR S&P 500 ETF Trust Oct3 370.0 Pput | $0 | – | -400,000 | -100.0% | -54.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.